Evaluation of a Novel Macromolecular Cascade-Polymer Contrast Medium for Dynamic Contrast-Enhanced MRI Monitoring of Antiangiogenic Bevacizumab Therapy in a Human Melanoma Model

Academic Radiology

Volumn 20, Issue 10, 2013, Pages 1256-1263

  Cyran, Clemens C ^a,b   Fu, Yanjun ^a   Rogut, Victor ^a   Chaopathomkul, Bundit ^a   Wendland, Michael F ^a   Shames, David M ^a   Brasch, Robert C ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Anti angiogenesis effect; Bevacizumab; Dynamic MRI; Gadolinium polyethylene glycol polymer contrast agent; Human melanoma xenograft

Indexed keywords

ALBUMIN; BEVACIZUMAB; CONTRAST MEDIUM; GADOLINIUM; MACROGOL; PENTETIC ACID; TETRAXETAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC IMAGING; EVALUATION; MACROMOLECULE; MELANOMA; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RAT; SUSCEPTIBILITY WEIGHTED IMAGING; SYNTHESIS; TUMOR XENOGRAFT;

ANTI-ANGIOGENESIS EFFECT; BEVACIZUMAB; DYNAMIC MRI; GADOLINIUM POLYETHYLENE GLYCOL POLYMER CONTRAST AGENT; HUMAN MELANOMA XENOGRAFT;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; CAPSULES; CELL LINE, TUMOR; CONTRAST MEDIA; DRUG MONITORING; HETEROCYCLIC COMPOUNDS; HUMANS; MACROMOLECULAR SUBSTANCES; MAGNETIC RESONANCE IMAGING; MELANOMA; NEOVASCULARIZATION, PATHOLOGIC; ORGANOMETALLIC COMPOUNDS; POLYETHYLENE GLYCOLS; RATS; RATS, NUDE; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

EID: 84883509148     PISSN: 10766332     EISSN: 18784046     Source Type: Journal    
DOI: 10.1016/j.acra.2013.07.010     Document Type: Article

References (33)

1. Ratain M.J., Eisen T., Stadler W.M., et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2006, 24:2505-2512. 10.1200/JCO.2005.03.6723.
2. Wahl R.L., Jacene H., Kasamon Y., et al. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med 2009, 50(Suppl 1):122S-150S. 50/Suppl_1/122S [pii] 10.2967/jnumed.108.057307.
3. Brasch R., Pham C., Shames D., et al. Assessing tumor angiogenesis using macromolecular MR imaging contrast media. J Magn Reson Imaging 1997, 7:68-74.
4. Cyran C.C., Sennino B., Chaopathomkul B., et al. Magnetic resonance imaging for monitoring the effects of thalidomide on experimental human breast cancers. Eur Radiol 2009, 19:121-131.
5. Fournier L.S., Novikov V., Lucidi V., et al. MR monitoring of cyclooxygenase-2 inhibition of angiogenesis in a human breast cancer model in rats. Radiology 2007, 243:105-111.
6. Pham C.D., Roberts T.P., van Bruggen N., et al. Magnetic resonance imaging detects suppression of tumor vascular permeability after administration of antibody to vascular endothelial growth factor. Cancer Invest 1998, 16:225-230.
7. Grist T.M., Korosec F.R., Peters D.C., et al. Steady-state and dynamic MR angiography with MS-325: initial experience in humans. Radiology 1998, 207:539-544.
8. Henderson E., Sykes J., Drost D., et al. Simultaneous MRI measurement of blood flow, blood volume, and capillary permeability in mammary tumors using two different contrast agents. J Magn Reson Imaging 2000, 12:991-1003.
9. Li D., Zheng J., Weinmann H.J. Contrast-enhanced MR imaging of coronary arteries: comparison of intra- and extravascular contrast agents in swine. Radiology 2001, 218:670-678.
10. Bumb A., Brechbiel M.W., Choyke P. Macromolecular and dendrimer-based magnetic resonance contrast agents. Acta Radiol 2010, 51:751-767. 10.3109/02841851.2010.491091.
11. Ye Z., Wu X., Tan M., et al. Synthesis and evaluation of a polydisulfide with Gd-DOTA monoamide side chains as a biodegradable macromolecular contrast agent for MR blood pool imaging. Contrast Media Mol Imaging 2013, 8:220-228. 10.1002/cmmi.1520.
12. Lim J., Turkbey B., Bernardo M., et al. Gadolinium MRI contrast agents based on triazine dendrimers: relaxivity and invivo pharmacokinetics. Bioconjug Chem 2012, 23:2291-2299. 10.1021/bc300461r.
13. Raatschen H.J., Fu Y., Shames D.M., et al. Magnetic resonance imaging enhancement of normal tissues and tumors using macromolecular Gd-based cascade polymer contrast agents: preclinical evaluations. Invest Radiol 2006, 41:860-867.
14. Cyran C.C., Fu Y., Raatschen H.J., et al. New macromolecular polymeric MRI contrast agents for application in the differentiation of cancer from benign soft tissues. J Magn Reson Imaging 2008, 27:581-589.
15. Fu Y., Raatschen H.J., Nitecki D.E., et al. Cascade polymeric MRI contrast media derived from poly(ethylene glycol) cores: initial syntheses and characterizations. Biomacromolecules 2007, 8:1519-1529. 10.1021/bm061141h.
16. Cai J., Han S., Qing R., et al. In pursuit of new anti-angiogenic therapies for cancer treatment. Front Biosci 2011, 16:803-814.
17. Rose S. FDA pulls approval for avastin in breast cancer. Cancer Discovery 2011, 1:OF1-OF2. 10.1158/2159-8290.CD-ND112311OL-08.
18. Dienstmann R., Ades F., Saini K.S., et al. Benefit-risk assessment of bevacizumab in the treatment of breast cancer. Drug Saf 2012, 35:15-25.
19. Shames D.M., Kuwatsuru R., Vexler V., et al. Measurement of capillary permeability to macromolecules by dynamic magnetic resonance imaging: a quantitative noninvasive technique. Magn Reson Med 1993, 29:616-622.
20. Fu Y., Nitecki D.E., Maltby D., et al. Dendritic iodinated contrast agents with PEG-cores for CT imaging: synthesis and preliminary characterization. Bioconjug Chem 2006, 17:1043-1056.
21. Ogan M.D., Schmiedl U., Moseley M.E., et al. Albumin labeled with Gd-DTPA. An intravascular contrast-enhancing agent for magnetic resonance blood pool imaging: preparation and characterization. Invest Radiol 1987, 22:665-671.
22. Roberts T.P., Brasch R.C., Schwickert H.C., et al. Quantification of tissue gadolinium concentration using magnetic resonance imaging: comparison of ultrashort inversion time inversion recovery echoplanar and dynamic three-dimensional spoiled gradient-recalled approaches with invitro measurements. Acad Radiol 1996, 3(Suppl 2):S282-S285.
23. Preda A., Turetschek K., Daldrup H., et al. The choice of region of interest measures in contrast-enhanced magnetic resonance image characterization of experimental breast tumors. Invest Radiol 2005, 40:349-354.
24. Stephen R.M., Gillies R.J. Promise and progress for functional and molecular imaging of response to targeted therapies. Pharm Res 2007, 24:1172-1185. 10.1007/s11095-007-9250-3.
25. Menichetti L., Manzoni L., Paduano L., et al. Iron oxide-gold core-shell nanoparticles as multi-modal imaging contrast agent. IEEE Sensors J 2013, 13:2305-2312.
26. Casciaro S., Soloperto G., Greco A., et al. Effectiveness of functionalized nanosystems for multimodal molecular sensing and imaging in medicine. IEEE Sensors J 2013, 13:2305-2312.
27. Malvindi M.A., Greco A., Conversano F., et al. Magnetic/silica nanocomposites as dual-mode contrast agents for combined magnetic resonance imaging and ultrasonography. Adv Funct Mater 2011, 21:2548-2555.
28. Kiessling F., Farhan N., Lichy M.P., et al. Dynamic contrast-enhanced magnetic resonance imaging rapidly indicates vessel regression in human squamous cell carcinomas grown in nude mice caused by VEGF receptor 2 blockade with DC101. Neoplasia 2004, 6:213-223. 10.1593/neo.3394.
29. Turetschek K., Preda A., Novikov V., et al. Tumor microvascular changes in antiangiogenic treatment: assessment by magnetic resonance contrast media of different molecular weights. J Magn Reson Imaging 2004, 20:138-144.
30. Cyran C.C., Paprottka P.M., Schwarz B., et al. Perfusion MRI for monitoring the effect of sorafenib on experimental prostate carcinoma: a validation study. AJR Am J Roentgenol 2012, 198:384-391. 198/2/384 [pii] 10.2214/AJR.11.6951.
31. Afaq A., Akin O. Imaging assessment of tumor response: past, present and future. Future Oncol 2011, 7:669-677.
32. Cyran C.C., Sennino B., Fu Y., et al. Permeability to macromolecular contrast media quantified by dynamic MRI correlates with tumor tissue assays of vascular endothelial growth factor (VEGF). Eur J Radiol 2012, 81:891-896. 10.1016/j.ejrad.2011.07.016.
33. Dvorak H.F., Sioussat T.M., Brown L.F., et al. Distribution of vascular permeability factor (vascular endothelial growth factor) in tumors: concentration in tumor blood vessels. J Exp Med 1991, 174:1275-1278.